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Background: The aim of extracorporeal albumin dialysis (ECAD) is to reduce endogenous toxins accumulating in
liver failure. To date, ECAD is conducted mainly with the Molecular Adsorbents Recirculating System (MARS).
However, single-pass albumin dialysis (SPAD) has been proposed as an alternative. The aim of this study was to
compare the two devices with a prospective, single-centre, non-inferiority crossover study design with particular
focus on reduction of bilirubin levels (primary endpoint) and influence on paraclinical and clinical parameters
(secondary endpoints) associated with liver failure.
Methods: Patients presenting with liver failure were screened for eligibility and after inclusion were randomly
assigned to be started on either conventional MARS or SPAD (with 4 % albumin and a dialysis flow rate of 700 ml/h).
Statistical analyses were based on a linear mixed-effects model.
Results: Sixty-nine crossover cycles of ECAD in 32 patients were completed. Both systems significantly reduced plasma
bilirubin levels to a similar extent (MARS: median −68 μmol/L, interquartile range [IQR] −107.5 to −33.5, p = 0.001; SPAD:
−59 μmol/L, −84.5 to +36.5, p = 0.001). However, bile acids (MARS: −39 μmol/L, −105.6 to −8.3, p < 0.001; SPAD: −9
μmol/L, −36.9 to +11.4, p = 0.131), creatinine (MARS: −24 μmol/L, −46.5 to −8.0, p < 0.001; SPAD: −2 μmol/L, −9.0 to
+7.0/L, p = 0.314) and urea (MARS: −0.9 mmol/L, −1.93 to −0.10, p = 0.024; SPAD: −0.1 mmol/L, −1.0 to +0.68, p = 0.523)
were reduced and albumin-binding capacity was increased (MARS: +10 %, −0.8 to +20.9 %, p < 0.001; SPAD: +7 %, −7.5
to +15.5 %, p = 0.137) only by MARS. Cytokine levels of interleukin (IL)-6 and IL-8 and hepatic encephalopathy were
altered by neither MARS nor SPAD.
Conclusions: Both procedures were safe for temporary extracorporeal liver support. While in clinical practice routinely
assessed plasma bilirubin levels were reduced by both systems, only MARS affected other paraclinical parameters (i.e.,
serum bile acids, albumin-binding capacity, and creatinine and urea levels). Caution should be taken with regard to
metabolic derangements and electrolyte disturbances, particularly in SPAD using regional citrate anti-coagulation.
Trial registration: German Clinical Trials Register (www.drks.de) DRKS00000371. Registered 8 April 2010.
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Liver failure—acute or acute-on-chronic—is associated
with high mortality. According to the toxin hypothesis of
liver failure, extracorporeal albumin dialysis (ECAD) may
provide a therapeutic option during critical care by redu-
cing endogenous albumin-bound toxic agents such as bile
acids [1]. Currently, ECAD is mainly conducted using the
Molecular Adsorbents Recirculating System (MARS). Sev-
eral clinical trials have certified MARS as a feasible tool in
reducing patients’ bilirubin levels, improving haemo-
dynamic status and hepatic encephalopathy (HE) [2–4].
However, large clinical trials have failed to demonstrate a
survival benefit for patients treated with MARS [2, 4]. An-
other ECAD technique, single-pass albumin dialysis
(SPAD), has been proposed. This technique enables easy
access to extracorporeal liver support by using standard
dialysis devices [5]. In case reports and small clinical stud-
ies, researchers have reported the feasibility of SPAD in re-
ducing patients’ bilirubin levels and improving their
clinical condition (i.e., HE) [6]. However, while MARS is
routinely prepared with 600 ml of a 20 % albumin solution
according to manufacturers’ instructions, SPAD applica-
tions were reported to run on different albumin concen-
trations and dialysate flow rates [7, 8]. Thus, comparison
of both techniques requires clear definitions of SPAD con-
struction. Recently, our study group retrospectively com-
pared the effects of MARS and 4 % SPAD with a dialysis
flow rate of 700 ml/h on clinical and laboratory parame-
ters in critically ill patients [9]. Similar settings have
already been used in an in vitro comparison of MARS and
SPAD that resulted in equivalent detoxification [8].
Among others, in our retrospective study, both devices
were comparable in reducing bilirubin levels, but MARS
treatment resulted in higher renal dialysis capacity,
reflected by lower creatinine and urea levels after treat-
ment [9]. Moreover, the equivalence of both devices in
clinical routine was questioned, as chemical stabilizers
added to albumin solutions may reduce performance, es-
pecially during SPAD, while they are partially removed by
recirculation and purification in the MARS device [10, 11].
Thus, the aim of this study was to prospectively com-
pare the performance of MARS and 4 % SPAD treatment
in patients with severe liver failure using a single-centre
crossover design, with particular focus on clinical and la-
boratory parameters. As a primary endpoint, we hypothe-
sised non-inferiority in bilirubin reduction of SPAD in
comparison to MARS. Changes in laboratory and clinical




The study was designed as a single-centre, randomised,
controlled, replicated crossover study. On the basis of ourretrospective study comparing the efficacy of MARS and
SPAD treatment [9], power analysis revealed 64 extracor-
poreal liver support cycles to assess non-inferiority of
SPAD in reducing bilirubin levels in comparison to MARS
treatment. This parameter served as the primary endpoint
in the present analysis. Calculated with a 10 % dropout
rate, 70 liver support crossover cycles were planned for
patient recruitment. Thus, patients were randomised to
start on either MARS followed by SPAD treatment the fol-
lowing day or vice versa. If extracorporeal liver support
was deemed necessary in a patient after the first crossover
cycle, the patient could be randomised again for up to four
crossover cycles. The study was approved by the ethics
committee of Friedrich-Schiller University Hospital, Jena,
Germany (ID 2435-12/08) and registered at German Clin-
ical Trials Register (www.germanctr.de) (DRKS00000371),
where the study protocol can be found.
Patient recruitment
All patients in the surgical intensive care unit of Jena
University Hospital with diagnoses of acute liver failure,
acute-on-chronic liver failure or liver graft failure were
screened for study inclusion if ECAD was indicated by
the intensivist in charge. According to the department’s
standard operating procedure (SOP), ECAD was consid-
ered when patients with a pertinent diagnosis presented
the following signs and symptoms:
1. Plasma disappearance rate of indocyanine green
(PDRICG) <8–10 %/minute, and
2. Plasma bilirubin level >170 μmol/L, and
3. International normalised ratio (INR) >1.5 and/or
4. Symptoms of HE grade II or higher
Patients younger than 18 years of age were not eligible
for study inclusion. After written informed consent was
obtained from the patients or their legal representatives,
patients were randomised for ECAD via sealed opaque
envelopes to one of the study arms. Block randomisation
was performed with blocks of 4, 6 or 8.
ECAD procedure and blood sampling
Vascular access was obtained via a triple-lumen haemodi-
alysis catheter (Trilyse Expert; Vygon, Aachen, Germany)
introduced into the femoral, jugular or subclavian vein.
MARS and SPAD devices were built up as described pre-
viously [9]. Depending on patients’ haemodynamics, blood
flow rates were set at between 100 and 150 ml/minute in
both systems, with equal flow rates in the corresponding
crossover treatments. The MARS monitor (Gambro,
Lund, Sweden) was attached to a standard haemodialysis
machine (BM25; Edwards Lifesciences, Unterschleissheim,
Germany) and planned to run for a duration of 8 h ac-
cording to the manufacturer’s instructions. Albumin flow
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rates were adjusted to 2000 ml/h. For SPAD (multiFiltrate;
Fresenius Medical Care, Bad Homburg, Germany), dialysis
flow rates were set to 700 ml/h. One thousand millilitres
of fluid was removed from a 5000-ml dialysis solution
bag (Ci-Ca Dialysate K2 Plus in case of regional cit-
rate anti-coagulation or multiBic dialysate for heparin
anti-coagulation; Fresenius Medical Care) and replaced
with 1000 ml of 20 % albumin solution (CSL Behring,
Marburg, Germany) containing 19.2 g of human albumin;
125 mmol/L Na+; maximum 100 mmol/L Cl−, HCl or
NaOH for pH adjustment; 16 mmol/L caprylate; and 16
mmol/L N-acetyl-D,L-tryptophan. This resulted in a final
human albumin concentration of 4 %. Using a 5000-ml
dialysis solution bag, the flow rate of 700 ml/h resulted in
a treatment cycle of about 7 h. Blood anti-coagulation was
maintained either using regional citrate application or by
systemic infusion of unfractionated heparin. In case of re-
gional citrate anti-coagulation citrate (4 % sodium citrate;
Fresenius Kabi, Bad Homburg, Germany) was applied be-
fore the haemofilter with the aim of achieving a final
ionised postfilter calcium level of 0.25–0.35 mmol/L,
followed by calcium reversal (1 N calcium chloride solu-
tion; Serumwerk Bernburg AG, Bernburg, Germany). In
the absence of bleeding tendency and/or ongoing heparin
anti-coagulation, infusion rates of unfractionated heparin
were adjusted to a final activated clotting time of 140–200
seconds. Blood sampling and measurement of clinical or
paraclinical parameters were carried out no more than 30
minutes before or after ECAD, respectively. Blood samples
for routine laboratory parameters were immediately sent
to the clinical laboratory for measurement. Plasma sam-
ples for non-routine measurements were immediately
centrifuged (4700 U/minute, 4 °C) for 10 minutes. Serum
samples were centrifuged (4700 U/minute, 4 °C) for 10
minutes after 30 minutes of resting. All samples were kept
frozen at −80 °C until evaluation.
Clinical assessment
Haemodynamic parameters (i.e., arterial pressure, heart
rate and central venous pressure [CVP]), were recorded
before and after each ECAD cycle. Cardiac output, intra-
thoracic blood volume index (ITBI), extravascular lung
water index (ELWI) and systemic vascular resistance
index were recorded if extended haemodynamic monitor-
ing was implemented, using transpulmonary thermodilu-
tion (PiCCO; PULSION Medical Systems, Feldkirchen,
Germany) [12]. PDRICG was assessed after intravenous in-
jection of 0.25–0.5 mg/kg body weight of indocyanine
green using pulse dye densitometry (LiMON; PULSION
Medical Systems) [13]. HE grade using the Hepatic En-
cephalopathy Scoring Algorithm (HESA) [14] and the
Glasgow Coma Scale score [15] and Ramsay score [16]
were evaluated to detect neurological alterations. AcutePhysiology and Chronic Health Evaluation II, Simplified
Acute Physiology Score II and Sequential Organ Failure
Assessment scores were assessed daily to evaluate illness
severity and organ dysfunction [17].
Cytokine measurement
Bio-Plex Pro Human Cytokine 8-plex Assay (Bio-Rad
Laboratories, Hercules, CA, USA) was used to detect
human cytokines interleukin (IL)-2, IL-4, IL-6, IL-8, IL-
10, granulocyte-macrophage colony-stimulating factor,
interferon-γ and tumour necrosis factor-α according to
the manufacturer’s instructions. Cytokines were measured
and analysed on a Bio-Plex 200 system running the
software Bio-Plex Manager 6.4 (Bio-Rad Laboratories).
Seventy-five particles per cytokine species were collected
and analysed. The standard curves were calculated using
five-parameter logistic regression.
Albumin-binding capacity
To address available site II–specific binding capacity of
albumin before and after each ECAD cycle, albumin-
binding capacity (ABiC) was measured in plasma sam-
ples as previously described [18].
Quantification of total bile acids
Serum total bile acid (TBA) levels were analysed using an
enzymatic colorimetric bile acid assay kit in accordance
with the manufacturer’s protocol (Abbott Laboratories,
Abbott Park, IL, USA). The analytical measurement range
was 1.0–200 μmol/L. Samples with TBA values exceeding
200 μmol/L were diluted manually (1:10) using 0.90 % NaCl.
Statistical analysis
The prospective study was designed as a non-inferiority
replicated crossover trial with up to four replications
where an inferiority of at least 10 % was regarded as
clinically relevant. The sample size calculations were
based on the data of 50 patients of the retrospective
pilot study [9]. The data suggested a log-normal distri-
bution for the bilirubin concentrations, an expected ratio
of 1 for the means of the two treatments and an intra-
subject coefficient of variation of 22.5 %. Furthermore,
we requested a type I error of 5 %, leading to 70 cycles
of MARS and SPAD to achieve a power of 80 %, includ-
ing a 10 % dropout rate. The sample size calculations
and the statistical analysis by means of linear mixed-
effect models were performed with R statistical software
[19]. We applied the R package bear [20] for the sample
size calculations and R packages lme4 [21] and lmerTest
[22] for the statistical analysis. Changes in laboratory
and clinical parameters before and after treatment were
compared using the Wilcoxon signed-rank test. Data are
expressed as median (25th and 75th percentiles) or fre-
quencies, if not otherwise specified.
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Study population
Between 15 August 2010 and 23 February 2013, 33 pa-
tients were enrolled in this clinical study. While in 54
patients ECAD was not indicated and/or initiated by the
intensivist in charge, screening failed in 117 patients pre-
dominantly because of inclusion in other interventional
clinical trials (see Fig. 1). One patient underwent a
highly urgent liver transplant after randomisation and
failed to complete the crossover ECAD cycle and thus
was excluded from analysis. Demographic data and base-
line characteristics of the study population are summa-
rized in Table 1. According to our SOP, all patients
fulfilled the aforementioned ECAD criteria before ran-
domisation for each cycle: PDRICG 3.9 %/minute (2.58–
4.98), total bilirubin 334 μmol/L (263.0–397.0), INR 1.6
(1.30–2.05) and HESA grade III (1.0–4.0).
Performance of ECAD
In total, 69 crossover cycles of ECAD were performed,
each consisting of 1 MARS and 1 SPAD treatment. The
median durations were 8:00 h (7:55–08:22) for MARS
vs. 7:15 h (7:00–7:30) for SPAD (p = 0.001). Blood anti-
coagulation was maintained mainly with regional citrate
infusion (n = 52 cycles in MARS vs. n = 54 cycles in
SPAD; p = 0.414), while unfractionated heparin was a
minor choice (n = 17 in MARS vs. n = 15 in SPAD)
for blood anti-coagulation. Median application of
ECAD was 2 (1–4) cycles, with a minimum of 1 and a
maximum of 4 cycles per patient as outlined in the study
protocol.Fig. 1 Flowchart of participants within the study period. ECAD extracorpore
Adsorbents Recirculating SystemEffect of MARS and SPAD on paraclinical parameters
Liver laboratory parameters
Both systems led to a significant reduction of total plasma
bilirubin levels without significant differences between the
two devices (p = 0.3). Moreover, we could not find any
period (p = 0.5) or carryover effects (p = 0.1) regarding the
bilirubin reduction. TBA concentrations were significantly
reduced by MARS application, while SPAD resulted in a
non-significant reduction (see Table 2 and Fig. 2). After
MARS, levels of γ-glutamyl transferase (GGT) were sig-
nificantly reduced; after SPAD, levels of GGT remained
unchanged. Reduction of GGT was significantly different
between the devices (p = 0.019) (see Table 2). All other in-
vestigated paraclinical liver enzymes (alanine aminotrans-
ferase, aspartate aminotransferase, alkaline phosphatase,
glutamate dehydrogenase, cholinesterase, ammonia and
coagulation factor V) demonstrated either marginal or no
changes during ECAD application and thus revealed no
significant differences between the two devices. These data
are provided in Additional file 1: Table S1.
Impact on surrogates for kidney function
The majority (91 %) of patients displayed moderate to
severe renal dysfunction according to the Acute Kidney
Injury Network (AKIN) criteria [23], and 60 % were on
haemodialysis before study inclusion (see Table 1). As
markers of residual renal function, median urine output
before study inclusion was 477 ml/24 h (63.8–1042.5],
accompanied by elevated levels of creatinine (170 μmol/L
[112.5–223.5]) and urea (16.3 mmol/L [9.80–21.38]). On
the day albumin dialyses were performed, 24-h urineal albumin dialysis, GIB gastrointestinal bleeding, MARS Molecular
Table 1 Patient characteristics at study inclusion
Characteristics Data
Age, yr
Median (IQR) 56 [50–64]
Minimum/maximum 25/75
Male sex, n (%) 18 (56.3)
Outcome, n (%)
ICU survival 12 (37.5)
Hospital survival 11 (34.4)
Scores at study inclusion, mean ± SD
APACHE II 21 ± 6.8
SAPS II 54 ± 16.6
SOFA 13 ± 4.4





Haemodialysis before study inclusion 19 (59.4)
Liver failure, n (%)
Acute-on-chronic 18 (56.3)
Acute 9 (28.1)
Liver graft failure 5 (15.6)
ICU intensive care unit, APACHE II Acute Physiology and Chronic Health
Evaluation II, SAPS II Simplified Acute Physiology Score II, SOFA Sequential
Organ Failure Assessment, AKIN Acute Kidney Injury Network, SD standard
deviation, IQR interquartile range
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278 ml/24 h, 25.0–732.5; SPAD: 300 ml/24 h, 21.0–988.0).
Regarding dialysis capacity, MARS resulted in significant
reduction of plasma creatinine levels, while SPAD did not
significantly reduce plasma creatinine (see Table 2 and
Fig. 2). For plasma urea levels, the same pattern wasTable 2 Liver laboratory parameters, cytokines and kidney retention
MARS, median (IQR)
Before After Dif
Bilirubin, μmol/L 323 (255.5–372.0) 249 (192.0–286.5) *
GGT, μmol/L 1.69 (0.805–4.567) 1.52 (0.760–4.125) *
TBA, μmol/L 119 (51.6–245.1) 75 (30.9–167.0) *
ABiC, % 67 (55.2–80.6) 76 (67.5–90.4) *
IL-6, pg/ml 142 (62.4–358.9) 123 (63.0–268.8) n.s
IL-8, pg/ml 66 (46.2–100.9) 65 (49.7–94.9) n.s
Creatinine, μmol/L 132 (85.5–186.5) 101 (64.0–145.9) *
Urea, mmol/L 11.6 (7.13–17.10) 10.5 (6.60–15.30) *
ECAD extracorporeal albumin dialysis, MARS Molecular Adsorbents Recirculating Sys
bile acid, ABiC albumin-binding capacity, IQR interquartile range, IL interleukin, n.s. n
*p < 0.05 significant changes within ECAD
**p < 0.05 significant differences between both devicesobserved. MARS led to a higher reduction in kidney re-
tention parameters than SPAD (p < 0.001 for creatinine
and p < 0.001 for urea, respectively).
Albumin-binding capacity
ABiC, as a marker of functional status of the albumin
molecule, significantly increased during MARS adminis-
tration, but it remained unchanged in SPAD application.
Changes of ABiC values were significantly different be-
tween the systems (p = 0.025), whereas human serum al-
bumin levels did not change during treatment (see also
Fig. 2 and Table 2).
Cytokine removal
To evaluate cytokine removal by ECAD, various human
cytokine levels were determined before and after each
cycle. However, only human IL-6 and IL-8 levels were
frequently elevated. Neither MARS nor SPAD resulted
in significant cytokine reduction, and there was no dif-
ference between the two ECAD devices (Table 2 and
Additional file 1: Figure S1). Moreover, neither the cit-
rate nor the heparin anti-coagulation strategy had an im-
pact on IL-6 or IL-8 removal (Additional file 1: Table S2).
Acid–base status and electrolytes
Median pH values significantly increased during SPAD
application (p < 0.001). Increased levels of standard bi-
carbonate (SBC) and base excess (BE) pointed to a non-
respiratory cause of pH increase during the SPAD
procedure. MARS led to only non-significant changes in
pH, SBC and BE levels. Lactate levels increased during
the application of both devices. While MARS led to an
increase of 0.3 mmol/L (−0.18 to +0.58), lactate levels
increased during SPAD by 0.6 mmol/L (0.05–1.00). Re-
garding parameters of acid–base status, only lactate
levels showed significant differences between the devices
(p = 0.041). During the use of both devices, medianparameters before and after ECAD
SPAD, median (IQR)
ference Before After Difference
315 (249.5–389.5) 243 (199.5–309.5) *
1.66 (0.760–3.960) 1.53 (0.795–4.020) **
105 (58.1–218.9) 97 (50.7–202.4) **
66 (57.4–77.8) 71 (60.3–81.1) **
. 185 (94.3–369.8) 173 (55.9–385.8) n.s.
. 70 (46.6–124.5) 68 (45.6–108.1) n.s.
139 (79.0–201.5) 146 (83.0–199.8) **
12.8 (8.35–18.10) 13.4 (8.93–16.88) **
tem, SPAD single-pass albumin dialysis, GGT γ-glutamyl transferase, TBA total
on-significant
Fig. 2 Changes in laboratory parameters representing the primary and secondary study endpoints. Total bilirubin levels, albumin-binding capacity
(ABiC), total bile acid concentrations and creatinine levels during albumin dialysis, separated by the applied extracorporeal albumin dialysis (ECAD)
systems Molecular Adsorbents Recirculating System (MARS) or single-pass albumin dialysis (SPAD). Box plots represent overall values including all
69 performed ECAD cycles, while bounded dots mark changes of each individual ECAD application. *p < 0.05 significant changes within ECAD;
#p < 0.05 significant differences between both devices. n.s. non-significant difference
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sium levels (MARS: p = 0.027; SPAD: p = 0.005) signifi-
cantly decreased, while sodium (p < 0.001) and glucose
(p = 0.003) levels showed an increase only during SPAD.
The differences in calcium and sodium levels were signifi-
cantly different when both devices were compared (see
Table 3 and Fig. 3). Using the equation published by
Fazekas et al. [24], we found that osmolality significantly
differed when we compared both devices (p < 0.001). While
SPAD led to an increase (p < 0.001), osmolality remained
unchanged during MARS (p = 0.252) (Table 3 and Fig. 3).Separating anti-coagulation strategies (heparin vs. citrate)
in both systems, citrate application during SPAD led to sig-
nificant metabolic changes towards non-respiratory alkal-
osis (indicated by pH, BE and SBC increase) accompanied
by an increase of lactate and a decrease in systemic ionized
calcium levels. Moreover, sodium levels and osmolality also
increased during SPAD using citrate anti-coagulation. In
contrast, neither heparin application in either device nor
citrate infusion during MARS led to similar disturbances
in acid–base states, electrolyte balance or osmolality (see
Additional file 1: Table S2).
Table 3 Acid–base parameters and electrolytes before and after ECAD
MARS, median (IQR) SPAD, median (IQR)
Pre-ECAD Post-ECAD Difference Pre-ECAD Post-ECAD Difference
pH 7.42 (7.374–7.447) 7.42 (7.390–7.449) n.s. 7.40 (7.356–7.424) 7.43 (7.386–7.454) *
SBC, mmol/L 27.3 (24.03–31.48) 27.5 (24.70–30.60) n.s. 25.1 (22.75–27.50) 27.8 (24.45–30.60) *
Base excess, mmol/L 3.9 (0.03–8.35) 3.8 (0.70–7.20) n.s. 1.3 (−1.40/+3.85) 4.0 (0.40/7.65) *
Lactate, mmol/L 1.9 (1.30–2.70) 2.1 (1.70–3.00) * 1.8 (1.30–2.75) 2.5 (1.70–3.60) *,**
Sodium, mmol/L 142 (138.3–146.0) 143 (139.0–147.0) n.s. 141 (136.5–146.0) 144 (139.0–148.5) *,**
Potassium, mmol/L 4.5 (4.20–4.70) 4.2 (3.90–4.60) * 4.4 (4.15–4.70) 4.2 (3.90–4.60) *
Calcium, mmol/L 1.24 (1.140–1.330) 1.15 (1.090–1.260) * 1.21 (1.115–1.310) 1.06 (0.890–1.145) *,**
Glucose, mmol/L 6.9 (5.70–8.00) 7.3 (6.15–8.05) n.s. 6.6 (6.00–7.80) 7.5 (6.50–8.80) *
Osmolality, mOsmol/kg H2O 305.1 (295.85–320.79) 305.7 (297.24–319.79) n.s. 304.5 (294.53–312.01) 310.1 (299.76–319.85) *
,**
ECAD extracorporeal albumin dialysis, MARS Molecular Adsorbents Recirculating System, SPAD single-pass albumin dialysis, SBC standard bicarbonate, IQR interquartile
range, n.s. non-significant
*p < 0.05 significant changes within ECAD
**p < 0.05 significant differences between both devices
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Levels of haemoglobin (MARS: p = 0.002; SPAD: p =
0.005), haematocrit (MARS: p = 0.005; SPAD: p = 0.016)
and INR (MARS: p = 0.449; SPAD: p = 0.049) changed
only slightly during ECAD, showing no significant differ-
ences between the devices. However, platelets signifi-
cantly decreased during MARS (−8, −18.9 to +1.5; p <
0.001), but not during SPAD application (−2, −11.5 to
+9.0; p = 0.286) and thus were significantly different be-
tween both devices (p = 0.032) (see Additional file 1:
Table S3).
Effect of MARS and SPAD on clinical parameters
Hepatic encephalopathy and neurological scoring
HE was analysed using the HESA score, consciousness
was evaluated by Glasgow Coma Scale score and grade
of sedation was assessed using the Ramsay score. All of
these parameters were similar between the devices and
showed no significant changes during the administration
of MARS or SPAD. Moreover, separating ECAD cycles
under sedative medication (n = 20) from cycles without
sedative medication (n = 49) revealed no changes in any
of the aforementioned scores after completion of one
crossover cycle (MARS and SPAD or vice versa) (for
convenience, see Additional file 1: Table S4).
Haemodynamic parameters
Mean arterial pressure increased during ECAD applica-
tion, but only in SPAD did it reach statistical signifi-
cance. However, we found no significant difference when
we compared both ECAD devices. All other values in
the haemodynamic profile (i.e., heart rate, CVP, central
venous oxygen saturation and dosage of vasopressor
support) were similar before and after each ECAD cycle
and thus also showed no significant differences between
the devices. In 13 MARS cycles and 15 SPAD cycles,patients had intensified haemodynamic monitoring using
transpulmonary thermodilution. The values for cardiac
index, ELWI and ITBI were comparable before and after
each ECAD cycle as well as between the devices (see
Additional file 1: Table S5).
Thermal balance
Evaluation of thermal balance during application of both
devices revealed slightly increasing body temperature
under MARS application (+0.3 °C, −0.15 to +0.75) com-
pared with SPAD treatment (−0.1 °C, −0.55 to +0.35).
Transfusion rates during ECAD
The median transfusion rates were 1 (0–1) for erythro-
cytes, 0 (0–0) for fresh frozen plasma and 0 (0–0) for
platelets, without differences between the devices.
Discussion
Following the autointoxication hypothesis of liver failure
[1], the aim of using liver support systems is to reduce
endogenous liver toxins. They carry the potential to re-
duce not only water-soluble toxic substances (e.g., by
means of conventional haemodialysis) but also hydro-
phobic agents (e.g., by using albumin as a dialysis solu-
tion). Due to its biochemical structure, albumin is able
to bind numerous endo- and exogenous substrates, such
as bilirubin and bile acids [25], that can thus be cleared
via ECAD (i.e., MARS or SPAD).
In this prospective crossover study, we compared these
two extracorporeal liver support systems with a particu-
lar focus on their effect on bilirubin levels and further
clinical and laboratory parameters. We found equivalent
significant reductions in plasma bilirubin levels in both
MARS and 4 % SPAD, without differences between the
methods. Measurement of bilirubin, both unconjugated
and conjugated, is common in intensive care units to
Fig. 3 Changes in laboratory markers hinting to metabolic disturbances and electrolyte derangements in both extracorporeal albumin dialysis
(ECAD) devices. Box plots represent overall values including all 69 performed ECAD cycles, and bounded dots mark changes of each individual
ECAD application. MARS Molecular Adsorbents Recirculating System, SPAD single-pass albumin dialysis, n.s. non-significant difference
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Bilirubin levels were found to be associated with progno-
sis in the critical care setting [26] and particularly in
liver failure. With respect to extracorporeal liver support
therapy, bilirubin is often used as one of several parame-
ters to indicate therapy and, in addition, to assess effect-
ive elimination of albumin-bound substances. Bilirubin
can easily pass the haemodialysis filter; however, due to
its lipophilic structure and its low water solubility, a car-
rier is necessary to eliminate bilirubin via haemodialysis.
Human serum albumin, with its three bilirubin binding
sites [27], has a high capacity to remove bilirubin during
albumin dialysis. In a retrospective analysis, we had
found similar reduction rates of bilirubin in patientstreated with either MARS or SPAD [9]. We used these re-
sults for a sample size calculation and bilirubin thereby
became the primary endpoint in our present study.
Although not routinely assessed, other parameters,
such as bile acids or ABiC, might be of superior clinical
significance in defining excretory liver dysfunction com-
pared with bilirubin levels. For example, toxic bile acids
can induce hepatocyte and biliary epithelial cell necrosis
[28] and are therefore of potential prognostic significance
[29, 30]. Furthermore, they might contribute to remote
organ dysfunction such as cirrhotic cardiomyopathy [31]
or reduced systemic vascular resistance [32]. In contrast
to bilirubin levels, TBA concentrations were significantly
reduced only during MARS and not during SPAD
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acid concentrations in vivo [33–35]. In the case of SPAD,
two in vitro studies [8, 36] and one small uncontrolled
study [7] addressing the clearance of bile acids have been
published. Interestingly, in the study of Sauer et al. [8],
MARS and SPAD were comparable in bile acid clearance;
in the study of Benyoub et al. [7], bile acids were signifi-
cantly removed during a 10-h SPAD (3.2 % albumin con-
centration) procedure with a dialysate flow rate of 1000
ml/h. These results are in clear contrast to our findings,
the latter possibly being due to higher dialysate flow rate
and longer treatment period, resulting in a much higher
dialysis dose. One potential explanation for the dis-
crepancy in the in vitro studies could be the different
dialysis modes used (continuous venovenous haemo-
diafiltration in vitro vs. continuous venovenous haemodi-
alysis [CVVHD] in our study). However, with a molecular
weight of about 500 Da, bile acids should be removed
more effectively in the dialysis mode; indeed, Benyoub
et al. used CVVHD as well [7]. The more likely explan-
ation is an inherent limitation of the in vitro setting repre-
senting a one-compartment model (i.e., the intravascular
compartment). In vivo elimination of bile acids is compli-
cated by diffusion of bile acids from tissue and by ongoing
bile acid production. Differences in the effectiveness of
MARS and SPAD in removing bile acids could thereby be
unmasked.
With respect to potential toxicity of bile acids and the
higher removal rate of bile acids during MARS treat-
ment in our study, the reduction of GGT levels during
MARS could suggest bile duct regeneration, as high
levels of GGT correlate to bile duct lesions [37]. Thus, it
can be speculated that reduction and/or expression pat-
tern change of bile acids (i.e., allocation of conjugated to
unconjugated) could improve the disease course. How-
ever, recent large randomised clinical trials of extracor-
poreal liver support, in either acute or acute-on-chronic
liver failure [2, 4], did not focus on bile acid removal, so
further study would be needed to directly address this
possibility.
Human serum albumin is the major carrier protein for
a multitude of endogenous and exogenous substances.
Many accumulating substances in liver failure are trans-
ported bound to albumin. ABiC was developed to assess
the binding site II–specific binding capacity of human
serum albumin, the binding site of, for example, bile
acids [38]. ABiC correlated inversely with severity and
30-day mortality in patients with decompensated cirrho-
sis [18]. ABiC was exclusively increased during MARS
treatment in the present study. Such an improvement of
ABiC in MARS treatment was demonstrated previously
[39]. In the present study, SPAD was not able to im-
prove ABiC. These findings might be at least in part an
accompanying effect of the results seen in bile acids, ashigher bile acid levels with higher binding at binding site
II might lead to reduced ABiC. Another potential ex-
planation for this finding may be in the stabilizers added
to pharmaceutical albumin preparations. These stabi-
lizers may occupy binding sites of albumin (e.g., octano-
ate, which also binds to albumin binding site II). On the
one hand, these stabilizers can be bound to the adsorp-
tion columns in the albumin circuit in MARS, thereby
improving capacity to remove albumin-bound sub-
stances such as bile acids from the blood circuit. On the
other hand, the demonstrated higher increase of octano-
ate concentrations in blood of patients during SPAD
treatment may contribute to the less increased ABiC in
comparison to MARS treatment [11]. Of note, the albu-
min solution used in the present study contained the
stabilizer octanoate equivalent to caprylate. Whether re-
moving these stabilizers (e.g., by charcoal filters) before
albumin dialysis might overcome these shortcomings in
SPAD therapy remains elusive.
As acute or chronic renal insufficiency displays a com-
mon complication in liver dysfunction, removal of
water-soluble substances, such as urea and creatinine, is
often required during ECAD. However, assessment of
renal dysfunction by traditional scoring systems (i.e.,
AKIN criteria) is not always applicable [40], and some
patients require haemodialysis for reasons not related to
creatinine levels and urine output (e.g., hypervolemia or
acidosis). In the present study, the majority of the critic-
ally ill patient cohort required renal replacement therapy
before study inclusion. Thus, ECAD treatment was
coupled to conventional haemodialysis circuits. The abil-
ity to decrease water-soluble substances in our study
was higher in MARS than in SPAD treatment, most due
to differing dialysate flow rates among the ECAD devices
(MARS 2000 ml/h vs. SPAD 700 ml/h). In the clinical
setting, this might be of minor relevance, as it could eas-
ily be compensated for if a 7-h SPAD treatment were
followed by conventional continuous renal replacement
therapy using the same dialysing machine with conven-
tional dialysing solution and a higher dialysate flow rate.
However, it must be noted that variances in the reduc-
tion of water-soluble substances may also be altered by
residual endogenous renal function, possibly influencing
the efficacy of ECAD therapy. Nevertheless, due to the
crossover study design, the influence of either MARS or
SPAD on alteration of kidney retention parameters in
the present study may overcome these shortcomings.
Pro-inflammatory cytokines are suspected to induce
and/or augment hepatocellular damage and cholestasis,
thereby contributing to the course of liver failure [41].
However, there is evidence that growth factors and pro-
inflammatory cytokines are involved in liver regeneration
and proliferation of hepatocytes. Data regarding the in-
fluence of ECAD on systemic cytokine levels in patients
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ing [42–44]. Removal of cytokines via albumin dialysis
has been demonstrated. In addition, circulating cytokine
levels could be affected by either removal by dialysis or
induced changes in the rate of production. Moreover,
different anti-coagulation strategies could possibly alter
cytokine removal. Thus, elevated IL-8 levels were shown
to be removed via CVVHD under regional citrate anti-
coagulation, but not using heparin anti-coagulation. Inter-
estingly, IL-6 levels were altered by neither citrate nor
heparin anti-coagulation [45]. However, researchers in
other clinical studies could not find any differences re-
garding cytokine removal during conventional haemodi-
alysis using different anti-coagulation strategies [46, 47].
In this respect, combining albumin dialysis with a cytokine
adsorption filter may be superior regarding cytokine re-
moval [48]. However, the clinical relevance of elevated
cytokine levels in patients with liver failure is not fully
understood, as cytokines could enhance cell damage as
well as induce liver regeneration [43, 49, 50]. In our study,
elevated systemic cytokine levels were lowered neither
during MARS nor during SPAD application. Moreover,
neither citrate nor heparin anti-coagulation altered cyto-
kine levels in the present study.
Both systems were safe in providing extracorporeal liver
support in critically ill patients, particularly in view of
bleeding complications, transfusion rates and haemo-
dynamic stability. Clinically non-significant changes in
thermal balance may be explained by more pronounced
warming of the dialysate solution during MARS (two
heating devices: dialysis machine and MARS monitor)
compared with SPAD (one single heating during haemodi-
alysis). In SPAD treatment, we found higher rates of meta-
bolic derangement (increase in pH, BE and lactate values)
and electrolyte disturbances (decreasing calcium levels
and increasing sodium levels), resulting in osmolality dis-
placements. These changes were limited to patients re-
ceiving citrate anti-coagulation, hinting at a relative
overdosing of citrate [51], most likely due to the low di-
alysate flow rate of 700 ml/h in SPAD treatment and the
use of commercially available citrate solutions designed
for conventional haemodialysis. To compensate for this
apparent disadvantage (1) dialysate flow rates could be in-
creased or (2) lower concentrated sodium citrate solutions
during SPAD procedures running on regional citrate anti-
coagulation could be used. On one hand, increasing the
dialysate flow rate would reduce the treatment duration or
it must be accounted for by reducing the albumin content.
Increasing the albumin concentration as well as the dialys-
ate flow rate, on the other hand, would enhance costing of
SPAD, abolishing the savings of around €1500 per treat-
ment cycle using the described setting of our study in
comparison to MARS (only material costing, not includ-
ing personnel for device build-up).Regarding HE, patients scored a median of grade III
on the HESA scale of four grades and 14 on the Glasgow
Coma Scale, indicating presence of HE in the patient co-
hort. Albumin dialysis was not able to significantly affect
HE grade among the study population, although this was
shown before by Hassanein et al. [3]. Competitive seda-
tive medication allowing invasive mechanical ventilation
in this critically ill patient cohort may represent one ex-
planation for this negative finding. Moreover, the study
was not designed to improve HE. We evaluated HE
scores after each ECAD cycle, which was not expected
to provide enough detoxification capacity to alter the
HE course. This is consistent with the findings of the
study of Hassanein et al., in which most patients needed
at least two treatments before HE improved.
Two limitations of our study are its single-centre de-
sign and the relatively small number of patients. How-
ever, we made a careful sample size calculation based on
retrospective data from our institution. As liver failure is
a rare disease and patients who require extracorporeal
liver support must be selected carefully, the number of
potential study patients is limited. Therefore, we imple-
mented the possibility for multiple applications of up to
four crossover cycles of albumin dialysis per patient in
the study design. This was accounted for in the sample
size analysis. Moreover, the crossover study design re-
vealed some major advantages in the present analysis:
(1) there are no confounding factors with respect to
comparability between the control- and test-group, as
both were represented by the same patient/cycle, and (2)
requirements of type I or type II errors are generally
comparable in cross-crossover design studies compared
with parallel group trials, at a lower sample size [52]. In
addition, we assessed only a limited number of potential
outcome-relevant factors (i.e. cytokine, bile acid or bili-
rubin levels and ABiC). We cannot exclude that there
are significant differences regarding further parameters
potentially influenced by ECAD, such as plasma levels of
other toxic substances or other albumin-related factors
(e.g., heavy metal binding capacity). Furthermore, the de-
toxification efficiency of the closed albumin circuit
(MARS) and the open albumin-enriched dialysis system
(SPAD) are dependent on some confounding factors; for
example, high solute concentrations of albumin-bound
substances might result in early saturation of adsorbers
in MARS, while low concentrations might leave residual
adsorption capacity. However, in SPAD, higher solute
concentrations potentially will not lead to saturation of
the dialysis process. In addition, longer treatment times
or higher dialysate flow rates in principle could result in
higher clearance of substances, albeit accompanied by
higher treatment costs. The decision to run MARS in
the described setting was based on the manufacturer’s
recommendation for duration of MARS [1]. This approach
Sponholz et al. Critical Care  (2016) 20:2 Page 11 of 13was previously used in larger multicentre trials on acute
and acute-on-chronic liver failure, respectively [2, 4].
Treatment settings of SPAD were based on a previous
in vitro study and on our own retrospective in vivo ana-
lysis [8, 9]. To preclude further confounders, blood flow
rates were equal during respective MARS and SPAD treat-
ments. Moreover, the crossover design itself limits bias in
comparing an open against a closed system, as all patients
receive both treatments.
Conclusions
This prospective, randomised, controlled crossover study
demonstrated the investigated albumin dialysis proce-
dures to be safe for temporary extracorporeal liver sup-
port. Overall, both devices displayed comparable results
for most clinical and paraclinical parameters in our crit-
ically ill patient cohort, especially in light of bilirubin re-
duction. However, particular focus should be placed on
metabolic derangements and electrolyte disturbances in
case of regional citrate anti-coagulation and reduced
renal haemodialysis efficacy (i.e., creatinine and urea
levels) caused by reduced dialysis flow rates during
SPAD application. Increasing dialysis efficacy of SPAD
by increasing dialysate flow rate and extending treatment
duration might compensate for this disadvantage. How-
ever, this needs to be investigated further. In addition, it
would increase treatment costs of SPAD, thereby de-
creasing the cost savings in comparison to MARS.
Moreover, in view of recent aspects regarding the patho-
physiology of liver failure and consecutive remote organ
failure, it remains speculative if MARS may provide ad-
vantages over SPAD by reducing bile acid concentration
and improving ABiC. Thus, further studies addressing
the timing and duration of ECAD, particularly in view of
altering clinical and paraclinical parameters beyond biliru-
bin reduction (e.g., HE, cytokine removal, ABiC enhance-
ment and bile acid changes), are warranted. Furthermore,
meaningful clinical outcomes, such as patient survival,
time on mechanical ventilation, vasopressor support or
course of HE, should be addressed.
Key messages
 This prospective crossover study shows that both
albumin dialysis devices, MARS and SPAD, were
able to reduce patients’ bilirubin levels to the same
amount (primary study endpoint).
 Both investigated albumin dialysis procedures were
safe for temporary extracorporeal liver support.
 However, in view of recent aspects regarding the
pathophysiology of liver failure and consecutive
remote organ failure, MARS provided advantages in
reducing bile acid concentration and improving
ABiC. Particular focus should be placed on the reduced
renal haemodialysis efficacy for creatinine and urea
levels during SPAD application.
 Application of SPAD using conventional regional
citrate anti-coagulation should be performed with
caution and efficacy of treatment need to be
monitored more carefully, especially in light of
metabolic derangements, electrolyte balance and
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